IP Library Granted Patent US 6,844,008
Granted Patent B2
US 6,844,008 · App. 10/358,324 · Granted Jan 18, 2005

Tablet composition

Assignee: Ajinomoto Co., Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,844,008
App. No.
10/358,324
Granted
Jan 18, 2005
Kind
B2
Abstract

A tablet composition containing N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and a disintegrant, selected from a low substituted hydroxypropylcellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose and sodium croscaramellose sodium, is disclosed. This tablet composition is rapidly disintegrated in the stomach after the administration and absorbed without being influenced by meals to inhibit the rise of the blood sugar levels of diabetics after meals.

Claims (18)

1. A tablet comprising:

N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and a disintegrant selected from the group consisting of sodium carboxymethyl cellulose, calcium carboxymethyl cellulose and croscaramellose sodium.

2. The tablet claim 1 in a form in which the absorption of N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine is not significantly influenced by meals.

3. A method for inhibiting the rise of blood sugar comprising administering the tablet of claim 1 to a subject in need thereof.

4. The tablet of claim 1 , wherein said disintegrant is sodium carboxymethyl cellulose.

5. The tablet of claim 1 , wherein said disintegrant is calcium carboxymethyl cellulose.

6. The tablet of claim 1 , wherein said disintegrant is croscaramellose sodium.

7. The tablet of claim 1 , wherein said tablet further comprises a filler selected from the group consisting of lactose, starch, crystalline cellulose, calcium monohydrogen phosphate, light anhydrous silicic acid, titanium oxide, and magnesium aluminometasilicate.

8. The tablet of claim 1 , wherein said filler is at a concentration ranging from 10 to 90% by weight.

9. The tablet of claim 1 , wherein said tablet further comprises lactose.

10. The tablet of claim 1 , wherein N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine is present at a concentration of 5 to 50% by weight.

11. The tablet of claim 1 , further comprising a binder.

12. The tablet of claim 11 , wherein said binder is hydroxypropylcellulose.

13. The tablet of claim 12 , wherein hydroxypropylcelluloses is present at a concentration of 0.5 to 2% by weight.

14. The tablet of claim 1 , further comprising one or more additives selected from the group consisting of a filler, a disintegrator, a binder, a lubricant, a coating agent, a colorant, a corrigent, and a surfactant.

15. The method of claim 3 , wherein said disintegrant is sodium carboxymethyl cellulose.

16. The method of claim 3 , wherein said disintegrant is calcium carboxymethyl cellulose.

17. The method of claim 3 , wherein said disintegrant is croscaramellose sodium.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: AJINOMOTO CO., INC.
To: EA PHARMA CO., LTD.
Reel/Frame 039094/0087 →
Priority Claims (1)
JP 8-318541 · Nov 15, 1996 · national
Continuity (5)
Continuation 0992083000 · Aug 3, 2001
Division 0967289600 · Sep 29, 2000
Continuation 0931106000 · May 14, 1999
Continuation PCTJP970415200 · Nov 14, 1997
Related Publication 20030147951A1 · Aug 7, 2003